Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

25.0%

13 terminated/withdrawn out of 52 trials

Success Rate

60.6%

-25.9% vs industry average

Late-Stage Pipeline

17%

9 trials in Phase 3/4

Results Transparency

95%

19 of 20 completed trials have results

Key Signals

11 recruiting19 with results10 terminated

Enrollment Performance

Analytics

Phase 1

26(51.0%)

Phase 2

16(31.4%)

Phase 3

9(17.6%)

51Total

Phase 1(26)

Phase 2(16)

Phase 3(9)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (52)

Showing 20 of 52 trials

NCT07037771Phase 3Recruiting

A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)

Role: lead

NCT06880770Phase 3Recruiting

Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis

Role: lead

NCT05083364Phase 1Completed

Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease

Role: lead

NCT06700538Phase 1Recruiting

A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus

Role: lead

NCT07221344Phase 1Recruiting

Study of ARO-MAPT-SC in Healthy Subjects and Subjects With Early Alzheimer's Disease

Role: lead

NCT04998201Phase 2Completed

Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia

Role: lead

NCT06937203Phase 1Recruiting

A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus

Role: lead

NCT07241546Phase 2Recruiting

Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma

Role: lead

NCT06822790Phase 3Recruiting

Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia

Role: lead

NCT05276570Phase 1Completed

Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung Disease

Role: lead

NCT04720534Phase 2Completed

Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia

Role: lead

NCT06209177Phase 1Active Not Recruiting

Study of ARO-CFB in Adult Healthy Volunteers

Role: lead

NCT07473843Phase 3Not Yet Recruiting

Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia

Role: lead

NCT06796426Unknown

Treatment Protocol of Plozasiran in Adults With High-Risk Severe Hypertriglyceridemia (SHTG) and in Adults and Adolescents With FCS

Role: lead

NCT05902598Phase 3Completed

A Phase 3 Study of ARO-APOC3 / VSA001 / SAR449124 (Plozasiran) in Chinese Adults With Familial Chylomicronemia Syndrome

Role: collaborator

NCT06131983Phase 1Recruiting

Study of ARO-DUX4 in Adult and Adolescent Patients With Facioscapulohumeral Muscular Dystrophy Type 1

Role: lead

NCT06672445Phase 1Recruiting

Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2

Role: lead

NCT05089084Phase 3Active Not Recruiting

Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)

Role: lead

NCT02065336Phase 2Terminated

A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection

Role: lead

NCT02535416Phase 1Completed

A Study of ARC-520 at Varying Infusion Rates in Healthy Adult Volunteers

Role: lead